文献速递免疫规划传染病防控与疫情报告

佐剂选择影响埃博拉疫苗保护相关免疫标志物

Adjuvant selection impacts the correlates of vaccine protection against Ebola infection.
PubMed 文献 · Vaccine · 2020-05-06

该研究在小鼠模型中比较了Advax菊粉基佐剂配方(Advax1-4)增强埃博拉病毒样颗粒(VLP)疫苗保护的效果。含TLR9激动剂组分的Advax佐剂诱导高IgG应答并实现完全保护,保护持久至免疫后150天;Advax-2或-4单剂免疫即可保护。Advax佐剂组诱导更强的IFN-γ、TNF和IL-12信号,血清过继可转移保护,而pICLC佐剂组尽管ELISA IgG高却不能转移保护。

要点

  • 含TLR9激动剂的Advax佐剂可诱导高IgG并完全保护小鼠免受埃博拉攻击。
  • Advax-2或-4佐剂单剂VLP免疫即可提供保护,保护持久至150天。
  • pICLC佐剂组IgG高但血清不能转移保护,提示佐剂选择关键。

核心结论

  • Advax佐剂(含TLR9激动剂)增强的埃博拉VLP疫苗可诱导持久保护,且保护可通过血清转移。
  • pICLC佐剂虽诱导高ELISA IgG但不能转移保护,表明佐剂选择影响保护相关标志物。

研究设计与样本

  • 小鼠攻击模型,比较Advax1-4佐剂配方增强埃博拉VLP疫苗保护的效果。
  • VLP疫苗经两次肌肉注射免疫,部分组单剂免疫;评估IgG应答、保护及血清转移。

主要发现

  • 含TLR9激动剂的Advax佐剂组诱导高IgG应答,完全保护免受埃博拉病毒攻击。
  • 抗埃博拉IgG随时间下降,但保护持久,免疫后150天仍明显。
  • Advax-2或-4佐剂单剂VLP免疫后小鼠即获保护。
  • Advax佐剂VLP诱导更强的IFN-γ、TNF和IL-12信号。
  • Advax佐剂疫苗接种者血清可转移保护至naïve动物;pICLC佐剂组血清不能转移保护。

临床怎么用

  • 埃博拉VLP疫苗开发中应优先选择可诱导保护性抗体且能转移保护的佐剂如Advax。
  • 评估疫苗保护力时需关注佐剂对保护相关免疫标志物的影响,不能仅凭ELISA IgG水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The establishment of correlates of protection is particularly relevant in the context of rare, highly lethal pathogens such as filoviruses. We previously demonstrated that an Ebola glycoprotein virus-like particle (VLP) vaccine, when given as two intramuscular doses, conferred protection from challenge in a murine challenge model. In this study, we compared the ability of Advax inulin-based adjuvant formulations (Advax1-4) to enhance Ebola VLP vaccine protection in mice. After two immunizations, Advax-adjuvants that included a TLR9 agonist component induced high IgG responses, with complete protection against Ebola virus challenge. Although anti-Ebola IgG levels waned over time, protection was durable and was still evident 150 days post-immunization. Mice were protected after just a single VLP immunization with Advax-2 or -4 adjuvants. Advax-adjuvanted VLPs induced a stronger IFN-γ, TNF and IL-12 signature and serum transferred from Advax-adjuvanted vaccinees was able to transfer protection to naïve animals, showing that Ebola protection can be achieved by antibodies in the absence of cellular immunity. By contrast, serum from vaccinees incorporating a pICLC adjuvant did not transfer protection despite high IgG levels on ELISA. These data highlight the importance of adjuvant selection for development of a successful Ebola VLP vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Stronsky SM, Cooper CL, Steffens J, et al. Adjuvant selection impacts the correlates of vaccine protection against Ebola infection. Vaccine. 2020. PMID: 32418798. doi:10.1016/j.vaccine.2020.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。